Text Size

Assessing Ocular Surface Changes After Changing Glaucoma Medications

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
University of Colorado, Denver
ClinicalTrials.gov Identifier:
NCT00554411
First received: November 2, 2007
Last updated: January 29, 2013
Last verified: January 2013
History of Changes
  Purpose

hypothesis: changing to Travatan Z therapy increases the tear film break up time of subjects on Xalatan therapy presenting with ocular surface disease.


Condition
Glaucoma
Monotherapy With Xalatan From 1 to 18 Months
Ocular Surface Disease

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Assessing Changes at the Ocular Surface Following the Switch From Xalatan to Travatan Z.

Resource links provided by NLM:

MedlinePlus related topics: Glaucoma
Drug Information available for: Travoprost
U.S. FDA Resources

Further study details as provided by University of Colorado, Denver:

Primary Outcome Measures:
  • Change in Signs and Symptoms of Ocular Surface Disease [ Time Frame: 6 months ] [ Designated as safety issue: No ]

Enrollment: 22
Study Start Date: November 2007
Study Completion Date: August 2011
Primary Completion Date: August 2011 (Final data collection date for primary outcome measure)
Detailed Description:

Patients who have been taking Xalatan monotherapy to treat their glaucoma and presenting with ocular surface disease will be advised to switch their medication to Travatan Z. Test results will be record at the day that the medication was changed and at follow-up to determine if there is a measurable change in tear film break up, corneal staining and in the Ocular Surface Disease Index.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

patients will be selected from the ophthalmology clinic of the principal investigator

Criteria

Inclusion Criteria:

  • on Xalatan monotherapy from 1 t 18 months
  • 18 years of age or older
  • has been diagnosed with ocular surface disease

Exclusion Criteria:

  • special populations such as children, pregnant females, prisoners, etc.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00554411

Locations
United States, Colorado
Rocky Mountain Lions Eye Institute
Aurora, Colorado, United States, 80045-0510
Sponsors and Collaborators
University of Colorado, Denver
Investigators
Principal Investigator: Malik Y Kahook, M.D. Rocky mountain Lions Eye Institute
  More Information

No publications provided

Responsible Party: University of Colorado, Denver
ClinicalTrials.gov Identifier: NCT00554411     History of Changes
Other Study ID Numbers: 07-0757
Study First Received: November 2, 2007
Last Updated: January 29, 2013
Health Authority: United States: Institutional Review Board

Keywords provided by University of Colorado, Denver:
Travatan Z
glaucoma
tear film break up time

Additional relevant MeSH terms:
Glaucoma
Ocular Hypertension
Eye Diseases
Travoprost
 Antihypertensive Agents
Cardiovascular Agents
Therapeutic Uses
Pharmacologic Actions

ClinicalTrials.gov processed this record on May 23, 2013